Zydus receives positive USFDA report, schedules Q2 earnings call

Zydus Lifesciences Limited announced on October 29, 2025, it has received an Establishment Inspection Report (EIR) from the USFDA for its manufacturing facility in Baddi. This follows an inspection conducted from August 4 to 13, 2025. The facility received a "Voluntary Action Indicated" (VAI) classification, signifying a positive outcome, and the USFDA has concluded this inspection as closed.

In related news, Zydus Lifesciences will hold a board of directors meeting on Thursday, November 6, 2025, to consider and approve the unaudited financial results for the quarter and half-year ended September 30, 2025. Following the results, a Q&A session through a webinar will be hosted by managing director Dr. Sharvil Patel on the same day at 4:00 PM IST.

The trading window for the company's securities will remain closed until Saturday, November 8, 2025, reopening on Monday, November 10, 2025, for all directors and designated persons. The Q2 FY26 earnings presentation will be available on the company's website in the InvestorZone post-results announcement, with an audio recording and transcript of the earnings call also available subsequently.